IndieBio

NanoPlume is a biomaterial company focused on the large-scale production of innovative biomaterials, particularly Bio-Aerogel.

Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

BioMetallum is a biomining company that designs and develops solutions for extracting lithium and other metals.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Unibaio specializes in biodegradable nano-encapsulation technology aimed at optimizing agrochemical delivery while minimizing environmental impact. The company develops innovative materials that create micro-nanocapsules, which enhance the efficacy of fertilizers and pesticides by improving their uptake and reducing harmful chemical runoff. Unibaio's solutions enable pesticide manufacturers to adjust their formulations to comply with stringent environmental regulations without altering the active ingredients used by farmers. By using natural compounds such as shrimp waste and clay, Unibaio promotes a circular economy, contributing to lower application costs for farmers and improved agricultural yields. Their technology is applicable across various pesticide and fertilizer types, including traditional chemicals and organic options, ultimately supporting the agricultural sector in reducing toxicity and enhancing the health of crops.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Vader Nanotechnologies creates a high-throughput screening method for identifying strains that can consume specific contaminants. Vader Nanotechnologies uses automation, image processing and computer vision, and analytical chemistry to find organisms that can grow solely on PFAS and other difficult-to-break-down chemicals. Vader optimizes and improves the performance of these organisms using directed evolution techniques.

BioFeyn focuses on enhancing aquaculture by optimizing the feed for farmed fish. The company employs a specialized method of biodegradable nanoencapsulation that surrounds trace amounts of marine ingredients with naturally-derived compounds. This innovative approach improves digestion, absorption, and bioavailability of nutrients, ensuring that fish receive what they naturally consume in the ocean. By delivering essential nutrients and natural disease preventatives through a targeted delivery mechanism, BioFeyn aims to improve fish health and reduce environmental pollution. This method not only contributes to the sustainability of fish farming but also helps produce more nutritious fish for consumers.

Kraken Sense specializes in an automated pathogen detection platform that utilizes advanced nanotechnology and real-time qPCR technology to identify bacterial contamination. The company's innovative solution allows for autonomous sampling from various sources, including liquids, solids, and aerosols. Its user-friendly IoT-enabled dashboard and analytics tools facilitate low-cost monitoring, making pathogen detection accessible and efficient. By employing state-of-the-art calibration techniques and cloud-based encryption, Kraken Sense enables clients to monitor and respond to contamination in real-time, ensuring a safer environment across multiple applications.

Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

ViaeX creates biological nanofiltration systems for water and air which are 400% more efficient than current solutions and enable selective pollutant and bacteria targeting. These systems are biodegradable, low cost, and rapidly scalable to enable fast deployment in cities around the world facing serious pollution issues. Advances in nanotechnology have paved the way for innovations that can combat the 9 million annual deaths caused by water and air pollution and reduce the $1.4 trillion global economic loss due to pollution annually. At ViaeX Technologies, they are focused on developing nanofiltration solutions to provide industrial and municipal customers with energy efficient, environmentally friendly, and selective filtration systems. Their technological platform has been developed over many years of fundamental research at UC Berkeley and UC San Diego. Based on novel physical-chemistry breakthroughs they have designed a system that overcomes many disadvantages of traditional filters by utilizing the potential of nanotechnology.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and based in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that leverages proprietary nanoparticles with a unique multilayered structure. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's drug delivery systems are designed to enhance the specificity, efficacy, and safety of cancer treatments, providing healthcare providers with improved tools for targeted therapy.

ViaeX creates biological nanofiltration systems for water and air which are 400% more efficient than current solutions and enable selective pollutant and bacteria targeting. These systems are biodegradable, low cost, and rapidly scalable to enable fast deployment in cities around the world facing serious pollution issues. Advances in nanotechnology have paved the way for innovations that can combat the 9 million annual deaths caused by water and air pollution and reduce the $1.4 trillion global economic loss due to pollution annually. At ViaeX Technologies, they are focused on developing nanofiltration solutions to provide industrial and municipal customers with energy efficient, environmentally friendly, and selective filtration systems. Their technological platform has been developed over many years of fundamental research at UC Berkeley and UC San Diego. Based on novel physical-chemistry breakthroughs they have designed a system that overcomes many disadvantages of traditional filters by utilizing the potential of nanotechnology.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and based in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that leverages proprietary nanoparticles with a unique multilayered structure. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's drug delivery systems are designed to enhance the specificity, efficacy, and safety of cancer treatments, providing healthcare providers with improved tools for targeted therapy.